Loading...
Loading...
GBS| Name | Value |
|---|---|
| Revenues | 131.8K |
| Cost of Revenue | 393.6K |
| Gross Profit | -261.7K |
| Operating Expense | 2,664.3K |
| Operating I/L | -2,807.8K |
| Other Income/Expense | 169.2K |
| Interest Income | 0.1K |
| Pretax | -2,638.6K |
| Income Tax Expense | 1,646.4K |
| Net Income/Loss | -4,284.9K |
GBS Inc. is a biosensor diagnostic technology company operating in the Asia-Pacific and North America. The company specializes in developing biosensor technologies, including the Saliva Glucose Biosensor for diabetes management and the SARS-CoV-2 Biosensor for virus detection. Additionally, GBS Inc. offers a biosensor platform for various diagnostic modalities. The company generates revenue through the sale of its biosensor products and technology licensing. GBS Inc. also has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests.
